Series: The AI Evolution in Commercial Pharma

Over the last decade we have seen a transformation in global pharma's commercial model as the industry rightsized itself from the blockbuster era of the '90s and early millennia. The era of competing on share of voice enabled by armies of sales representatives calling on health care professionals evolved into smarter and more sophisticated strategies for deploying sales and marketing resources--and doing more with less. Over the same period, we have witnessed a significant evolution in the rise of advanced analytics and especially the talk and the promise of Artificial Intelligence (AI) in commercial pharma, so it's time to ask the question--Can AI really help pharma proposer? McKinsey tends to think so. In a report entitled "Artificial Intelligence in Business", they concluded that AI and analytics would contribute $440 Billion in potential annual value in the pharmaceutical and medical device sector, of which the major share of over $200B resulted in value released from marketing and sales.